The Enterprise Value as of November 2024 (TTM) for U.S. Stem Cell, Inc. (USRM) is 64.15K

According to U.S. Stem Cell, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 64.15K. This represents a change of -97.86% compared to the average of 3.00M of the last 4 quarters.

U.S. Stem Cell, Inc. (USRM) Historical Enterprise Value (quarterly & annually)

How has USRM Enterprise Value performed in the past?

The mean historical Enterprise Value of U.S. Stem Cell, Inc. over the last ten years is 9.43M. The current 64.15K Enterprise Value has changed -31.98% with respect to the historical average. Over the past ten years (40 quarters), USRM's Enterprise Value was at its highest in in the March 2018 quarter at 30.66M. The Enterprise Value was at its lowest in in the March 2023 quarter at 0.

U.S. Stem Cell, Inc. (USRM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of U.S. Stem Cell, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

U.S. Stem Cell, Inc. (USRM) Average Enterprise Value

How has USRM Enterprise Value performed in the past?

The current Enterprise Value of U.S. Stem Cell, Inc. (USRM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

U.S. Stem Cell, Inc. (USRM) Enterprise Value vs. Peers

How is USRM’s Enterprise Value compared to its peers?

U.S. Stem Cell, Inc.’s Enterprise Value is less than Adhera Therapeutics, Inc. (10.80M), less than AgeX Therapeutics, Inc. (19.70M), less than XOMA Corporation (339.22M), less than Lineage Cell Therapeutics, Inc. (131.69M), less than Nascent Biotech, Inc. (9.49M), less than ProtoKinetix, Incorporated (3.94M), less than RespireRx Pharmaceuticals Inc. (2.94M), less than Silo Pharma, Inc. (247.23K), less than VG Life Sciences Inc. (4.22M), less than PharmaTher Holdings Ltd. (19.01M), less than Regen BioPharma, Inc. (1.05M), less than Regen BioPharma, Inc. (15.21M), less than Mymetics Corporation (75.33M), less than Theralink Technologies, Inc. (19.38M), less than GB Sciences, Inc. (0), less than SciSparc Ltd. (1.83M), less than null (247.74K),

Build a custom stock screener for U.S. Stem Cell, Inc. (USRM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like U.S. Stem Cell, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

U.S. Stem Cell, Inc. (USRM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like U.S. Stem Cell, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.